Compare Amer Sports Inc (AS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amer Sports Inc vs ResMed Inc. — how do they compare? Amer Sports Inc trades at $33.45 (market cap $19.69B), while ResMed Inc. trades at $224.23 (market cap $32.61B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays a 1.17% dividend while Amer Sports Inc pays none. Which is the better fit depends on your goals.
| AS | RMD | |
|---|---|---|
Market Cap | $19.69B | $32.61B |
Sector | Technology | Health |
52-Week High | $41.96 | $293.73 |
52-Week Low | $29.54 | $182.82 |
Enterprise Value | $20.01B | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amer Sports (AS) trades at $33.67, down 6.91% over 24 hours, with a bearish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.38 and revenue growth of 32% year-over-year, and raised full-year guidance. Key financials show a net income margin of 6.5% and positive cash flow from operations of $729.8 million in 2025.
The outlook is supported by analyst consensus with 12 buy ratings and a $58.67 price target, but risks include high valuation multiples like a P/E of 42.3 and competitive pressures in the sports apparel sector. Near-term focus is on Q2 2026 earnings due August 18, 2026, which could drive volatility.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amer Sports Inc
Amer Sports is a global group of iconic sports and outdoor brands, including Arc'teryx, Salomon, Wilson, and Atomic. It designs and manufactures high-quality equipment, apparel, and footwear for athletes worldwide.
Read more on AS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
